Comparison of the Emetogenic Potential Between Cisplatin and Carboplatin in Combination with Alkylating Agents

The relationship between parameters of serotonin metabolism and emetogenic potential of platinum-based chemotherapy regimens

“…In contrast, elevated 5-HIAA levels can be measured over at least 48 h in carboplatin-treated patients. These findings, and also clinical reports [6,10], suggest that the patterns of emesis induced by carboplatin may differ from those observed after cisplatin. The present study does not prove an involvement of 5-HT in the pathophysiology of carboplatin-induced emesis occurring later than day 1, but does indicate a field for further research.…”

Serum protein and electrolyte imbalances are associated with chemotherapy induced neutropenia

“…Chemotherapeutic agents such as ifosfamide, cause potassium excretion through the proximal tubule and leads to proximal tubulopathy or Fanconi syndrome, and continue even after completion of chemotherapy regime [ 47 ]. Another study reported platinum-based chemotherapeutic agents to be responsible for inducing potassium excretion due to their adverse effects such as vomiting, diarrhoea, and nephrotoxicity [ 48 ]. Cancers such as small cell lung carcinoma (SCLC), thymus, and bronchial malignancies thyroid cancer secrete ectopic adrenocorticotropin hormone (ACTH) causing potassium wastage through kidneys by activating mineralocorticoid pathway due to increased cortisol secretion [ 49 , 50 , 51 ].…”

Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens

“…In this study, they reported emesis in 60 % of carboplatin-treated patients and 69 % if including nausea (versus 83 and 87 %, respectively, for cisplatin-treated patients) [10]. Interestingly, the incidence rates of "nausea and vomiting" adverse events reported in the two pivotal ovarian trials resulting in the approval of carboplatin in the early 1990s were 93 and 94 % (versus 98 and 96 % for cisplatin) [11][12][13].…”